ADME/Tox test and obesity
Researchers need to build a more humanized mouse model to evaluate the absorption, distribution, metabolism, and excretion of newly developed drugs in preclinical toxicity testing. These mouse models in vivo experiments are able to clear the important link among drug dosage, concentration, toxicity and so on.
A good mouse model, not only at the level of genes, but also in histology and phenotype is similar to human disease. It is the only way to reduce the risk of drug failure in expensive clinical trials.
Behavioral and developmental disorders(like Autism spectrum disorders)
ASDs is difficult to use the model to simulate, partly because in the human body it is very difficult to find the cause of the disease itself. Recently, scientists have found a gene that is associated with an increased risk of ASDs disease, which could lead to new animal models. On the other hand, the Patient Derived Xenograft (PDX) model has great potential for the development of personalized therapeutic drugs, and the full human source of the mouse immune system will drive a lot of possibilities in this field. This model can be used to study the immune regulation related diseases, and to provide a platform for evaluating the effectiveness of stem cell therapy.
In tumor treatment, many still do not meet the actual needs of the medical. The clinical trial success rate of cancer treatment is only about 5%. We still need a new model to develop new effective drugs and treatment programs to save the lives of thousands of patients.
There are hundreds of thousands of rare diseases in the world, but the number of patients with these rare diseases adds up, the total number is no longer rare. Because the funds invested in these diseases are limited, so the relevant model and the development of the drug rate themselves are very slow.
The development of gene sequencing technology has allowed researchers to discover a number of rare and even unique mutations. At the same time, the emergence of CRISPR technology allows scientists to edit these human mutations in mouse models faster, easier, and cheaper.